Search
While inhibiting the Hedgehog signaling pathway has typically been used in oncology, San Diego based Endeavor BioMedicines has one they believe is well suited for fibrotic diseases like IPF
John Hood, the successful biotech entrepreneur and Co-Founder and CEO of Endeavor, describes the biological hypothesis for Hedgehog inhibition in IPF and why he thinks ENV-101 is the right asset for it. It is currently in a phase 2b that will read towards the end of the year, and he believes the trial can show more than just a slowing of the disease. Coverage brought to you by
Jun 26
ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF
John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...
May 20, 2024
John Hood on Endeavor's $132.5M series C and hedgehog inhibition for IPF
He describes the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise.
Apr 26, 2024
.png){kind=logo}